MB-105 study (NCT06534060), a Phase 2, open-label, single-arm, multicenter clinical trial for patients with CD5-positive relapsed or refractory T-cell lymphoma (r/r TCL). The study uses a Simon two-stage design.
This trial is specifically for TCL Patients
The Phase 1 trial (NCT03081910) at BCM continues to enroll patients with T-cell acute lymphoblastic leukemia (T-ALL) through physician referrals.
Enrollment for this trial will remain available for T-ALL patients.
